C. Routhier

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

D. Louis, D. Dias-Santagata, M. Hoang, 2013, Human pathology.

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, M. Protopopova, S. Collins, 2022, Cancer Research.

Basal Cell Carcinoma With Osteosarcomatous Component

D. Dias-Santagata, M. Hoang, J. Tse, 2013, The American Journal of dermatopathology.

Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses

M. Damelin, R. Bukhalid, Kalli C Catcott, 2024, Nature communications.

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Jeremy R. Duvall, S. Collins, Phonphimon Wongthida, 2023, Molecular cancer therapeutics.